Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2

American Journal of Kidney Diseases

Volumn 32, Issue 4 SUPPL. 2, 1998, Pages

  Llach, F ^a   Keshav, G ^a   Goldblat, M V ^a   Lindberg, J S ^a   Sadler, R ^a   Delmez, J ^a   Arruda, J ^a   Lau, A ^a   Slatopolsky, E ^a  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

19 nor; Calcitriol; Chronic renal disease; End stage renal disease; Parathyroid hormone; Paricalcitol; Renal osteodystrophy; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

CALCITRIOL DERIVATIVE; ERGOCALCIFEROL DERIVATIVE;

ADULT; ARTICLE; BONE REMODELING; CALCIUM METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MULTICENTER STUDY; PARATHYROID HORMONE RELEASE; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; VITAMIN D METABOLISM;

EID: 0031794715     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9808143     Document Type: Article

References (15)